SIMILAR PATTERNS OF AMINO ACIDS FOR 3QXV_C_MTXC2000

List of similar pattern of amino acids derived from ASSAM search

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click link on the last column to view superposed patterns of amino acids in NGL viewer)
(Note that only 3-12 residue patterns can be used for ASSAM searches)

Filter list by:

	Hit	Macromolecule/ Organism	Pfam	Res.	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1kxt	IMMUNOGLOBULIN VHH FRAGMENT (Camelus dromedarius)	PF07686 (V-set)	6	VAL B 2 ALA B 24 MET B 34 ARG B 71 ASN B 73 ALA B 94	None	0.97A	3qxvC-1kxtB: 19.5	3qxvC-1kxtB: 68.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	1pz5	HEAVY CHAIN OF FAB (SYA/J6) (Mus musculus)	PF07654 (C1-set) PF07686 (V-set)	5	VAL B 2 ALA B 24 MET B 34 ARG B 71 VAL B 78	None	0.83A	3qxvC-1pz5B: 20.2	3qxvC-1pz5B: 51.52
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2aeq	FAB HEAVY CHAIN (Mus musculus)	PF07686 (V-set)	5	VAL H 2 MET H 34 ARG H 74 ASN H 76 VAL H 81	None	0.82A	3qxvC-2aeqH: 18.2	3qxvC-2aeqH: 33.96
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2fl5	IMMUNOGLOBULIN IGG1 HEAVY CHAIN (Homo sapiens)	no annotation	5	VAL H 2 ALA H 24 MET H 34 ARG H 71 ASN H 73	None	0.77A	3qxvC-2fl5H: 20.8	3qxvC-2fl5H: 35.50
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2jgv	TAGATOSE-6-PHOSPHATE KINASE (Staphylococcus aureus)	PF00294 (PfkB)	6	VAL A 239 ALA A 230 ARG A 238 SER A 222 VAL A 181 ALA A 277	None	1.08A	3qxvC-2jgvA: undetectable	3qxvC-2jgvA: 16.87
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2uzi	ANTI-RAS FV HEAVY CHAIN (Homo sapiens)	PF07686 (V-set)	5	VAL H 2 ALA H 24 MET H 34 ARG H 72 ASN H 74	None	0.79A	3qxvC-2uziH: 21.4	3qxvC-2uziH: 60.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2xa3	LLAMA HEAVY CHAIN ANTIBODY D7 (Lama glama)	PF07686 (V-set)	5	SER A 29 MET A 34 ASN A 73 VAL A 78 ALA A 94	SO4 A1114 (-2.7A) None None None None	0.80A	3qxvC-2xa3A: 21.2	3qxvC-2xa3A: 69.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3g9a	MINIMIZER (Camelus dromedarius)	PF07686 (V-set)	5	ALA B 24 MET B 34 ARG B 71 VAL B 78 ALA B 94	None	0.71A	3qxvC-3g9aB: 20.0	3qxvC-3g9aB: 64.93
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3k7u	ANTIBODY (Lama glama)	PF07686 (V-set)	5	MET A 34 ARG A 72 ASN A 74 VAL A 79 ALA A 98	None	0.28A	3qxvC-3k7uA: 22.1	3qxvC-3k7uA: 73.81
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3ln9	IMMUNOGLOBULIN HEAVY CHAIN ANTIBODY VARIABLE DOMAIN B10 (Camelidae)	PF07686 (V-set)	6	VAL A 2 ALA A 24 ARG A 72 ASN A 74 VAL A 79 ALA A 98	None	0.85A	3qxvC-3ln9A: 19.7	3qxvC-3ln9A: 67.94
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3piq	HUMAN MONOCLONAL ANTIBODY 2909 FAB HEAVY CHAIN (Homo sapiens)	no annotation	5	VAL H 2 ALA H 24 MET H 34 ARG H 71 ASN H 73	None	0.80A	3qxvC-3piqH: 19.6	3qxvC-3piqH: 56.82
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3qxu	ANTI-METHOTREXATE CDR1-3 GRAFT (Lama glama)	PF07686 (V-set)	7	VAL A 4 ALA A 26 SER A 30 MET A 36 ARG A 74 VAL A 81 ALA A 100	None	0.89A	3qxvC-3qxuA: 24.5	3qxvC-3qxuA: 96.03
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3qyc	VH DOMAIN OF IGG MOLECULE (Homo sapiens)	PF07686 (V-set)	5	ALA A 26 MET A 36 ARG A 74 ASN A 76 VAL A 81	None	0.73A	3qxvC-3qycA: 20.1	3qxvC-3qycA: 61.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3qyc	VH DOMAIN OF IGG MOLECULE (Homo sapiens)	PF07686 (V-set)	5	VAL A 4 ALA A 26 MET A 36 ARG A 74 VAL A 81	None	0.83A	3qxvC-3qycA: 20.1	3qxvC-3qycA: 61.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3r0m	LLAMA VHH A12 (Lama glama)	PF07686 (V-set)	6	ALA A 24 SER A 29 MET A 34 ASN A 73 VAL A 78 ALA A 94	None SO4 A 131 (-2.7A) None None None None	1.12A	3qxvC-3r0mA: 21.2	3qxvC-3r0mA: 70.54
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	3stb	SINGLE DOMAIN ANTIBODY VHH (Lama glama)	PF07686 (V-set)	6	ALA A 26 MET A 36 ARG A 73 ASN A 75 VAL A 80 ALA A 99	None	0.71A	3qxvC-3stbA: 22.5	3qxvC-3stbA: 70.77
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4dgy	HCV1 HEAVY CHAIN (Homo sapiens)	PF07654 (C1-set) PF07686 (V-set)	5	VAL H 2 ALA H 24 MET H 34 ARG H 71 ASN H 73	GOL H 302 (-4.1A) None None None None	0.80A	3qxvC-4dgyH: 20.6	3qxvC-4dgyH: 37.19
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4dka	SINGLE DOMAIN ANTIBODY VHH (Lama glama)	PF07686 (V-set)	6	ALA A 24 MET A 34 ARG A 72 ASN A 74 VAL A 79 ALA A 98	None	0.78A	3qxvC-4dkaA: 22.3	3qxvC-4dkaA: 73.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4eig	CA1698 CAMEL ANTIBODY FRAGMENT (Lama glama)	PF07686 (V-set)	6	ALA B 24 MET B 34 ARG B 71 ASN B 73 VAL B 78 ALA B 97	None	0.75A	3qxvC-4eigB: 20.5	3qxvC-4eigB: 66.94
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ej1	NB113 CAMELID ANTIBODY FRAGMENT (Lama glama)	PF07686 (V-set)	5	ALA C 24 MET C 34 ASN C 74 VAL C 79 ALA C 98	None	0.70A	3qxvC-4ej1C: 21.7	3qxvC-4ej1C: 74.22
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ej1	NB113 CAMELID ANTIBODY FRAGMENT (Lama glama)	PF07686 (V-set)	5	MET C 34 ARG C 72 ASN C 74 VAL C 79 ALA C 98	None	0.38A	3qxvC-4ej1C: 21.7	3qxvC-4ej1C: 74.22
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4fhb	NB179 (Lama glama)	PF07686 (V-set)	5	MET D 34 ARG D 72 ASN D 74 VAL D 79 ALA D 98	None	0.50A	3qxvC-4fhbD: 21.4	3qxvC-4fhbD: 71.32
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4fql	MONOCLONAL ANTIBODY CR8033 HEAVY CHAIN (Homo sapiens)	PF07654 (C1-set) PF07686 (V-set)	5	VAL H 2 ALA H 24 MET H 34 ARG H 71 ASN H 73	None	0.75A	3qxvC-4fqlH: 21.7	3qxvC-4fqlH: 59.69
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4gft	NANOBODY (Lama glama)	PF07686 (V-set)	5	MET B 36 ARG B 74 ASN B 76 VAL B 81 ALA B 100	None	0.26A	3qxvC-4gftB: 22.7	3qxvC-4gftB: 66.93
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4glr	ANTI-PTAU HEAVY CHAIN (Gallus gallus)	PF07654 (C1-set) PF07686 (V-set)	5	VAL H 2 MET H 34 ARG H 71 ASN H 73 VAL H 78	None	0.60A	3qxvC-4glrH: 21.1	3qxvC-4glrH: 30.30
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4hem	ANTI-BASEPLATE TP901-1 LLAMA VHH 02 (Lama glama)	PF07686 (V-set)	6	ALA E 24 MET E 34 ARG E 72 ASN E 74 VAL E 79 ALA E 98	None	0.68A	3qxvC-4hemE: 23.2	3qxvC-4hemE: 73.39
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4kfz	ANTI-LMO2 VH (Homo sapiens)	PF07686 (V-set)	6	VAL C 2 ALA C 24 SER C 28 MET C 34 ARG C 72 ASN C 74	None	0.90A	3qxvC-4kfzC: 20.1	3qxvC-4kfzC: 61.83
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4krm	NANOBODY/VHH DOMAIN 7D12 (Lama glama)	PF07686 (V-set)	5	ALA B 24 MET B 34 ARG B 72 VAL B 79 ALA B 98	None	0.70A	3qxvC-4krmB: 23.8	3qxvC-4krmB: 70.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4krm	NANOBODY/VHH DOMAIN 7D12 (Lama glama)	PF07686 (V-set)	5	MET B 34 ARG B 72 ASN B 74 VAL B 79 ALA B 98	None	0.34A	3qxvC-4krmB: 23.8	3qxvC-4krmB: 70.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4lhq	CAMELID NANOBODY (Vicugna pacos)	PF07686 (V-set)	5	SER B 28 MET B 34 ARG B 72 ASN B 74 VAL B 79	None	0.64A	3qxvC-4lhqB: 22.0	3qxvC-4lhqB: 63.28
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4n1h	CAMELID HEAVY-CHAIN ANTIBODY VARIABLE FRAGMENT CAB-F11N (Lama glama)	PF07686 (V-set)	5	ALA B 24 MET B 34 ASN B 74 VAL B 79 ALA B 98	None	0.69A	3qxvC-4n1hB: 21.6	3qxvC-4n1hB: 68.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4n1h	CAMELID HEAVY-CHAIN ANTIBODY VARIABLE FRAGMENT CAB-F11N (Lama glama)	PF07686 (V-set)	5	MET B 34 ARG B 72 ASN B 74 VAL B 79 ALA B 98	None	0.44A	3qxvC-4n1hB: 21.6	3qxvC-4n1hB: 68.50
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4nc1	A20.1 VHH (Lama glama)	PF07686 (V-set)	7	VAL C 9 ALA C 31 MET C 41 ARG C 79 ASN C 81 VAL C 86 ALA C 105	None	0.93A	3qxvC-4nc1C: 22.2	3qxvC-4nc1C: 70.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4nc2	B39 VHH (Lama glama)	PF07686 (V-set)	6	VAL B 2 ALA B 24 MET B 34 ARG B 71 ASN B 73 ALA B 97	None	0.73A	3qxvC-4nc2B: 23.2	3qxvC-4nc2B: 70.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ocr	CAP256-VRC26.01 HEAVY CHAIN (Homo sapiens)	PF07654 (C1-set) PF07686 (V-set)	5	VAL H 2 MET H 34 ARG H 71 ASN H 73 VAL H 78	None	0.53A	3qxvC-4ocrH: 21.7	3qxvC-4ocrH: 54.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ouo	ANTI BLA G 1 SCFV (Gallus gallus)	PF07686 (V-set)	6	VAL A 116 ALA A 138 MET A 148 ARG A 185 ASN A 187 VAL A 192	None	0.90A	3qxvC-4ouoA: 20.9	3qxvC-4ouoA: 27.27
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4p2c	NANOBODY 1, ANTI-F4+ETEC BACTERIA VHH VARIABLE REGION (Lama glama)	PF07686 (V-set)	6	VAL G 2 MET G 34 ARG G 71 ASN G 73 VAL G 78 ALA G 97	None	0.57A	3qxvC-4p2cG: 19.1	3qxvC-4p2cG: 70.97
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4p49	ANTIBODY SCFV B8 (Gallus gallus)	PF07686 (V-set)	6	VAL A 122 ALA A 144 MET A 154 ARG A 193 ASN A 195 VAL A 200	None	0.93A	3qxvC-4p49A: 22.0	3qxvC-4p49A: 51.88
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4qlr	LLAMA NANOBODY N02 VH DOMAIN (Lama glama)	PF07686 (V-set)	5	ALA A 24 ARG A 72 ASN A 74 VAL A 79 ALA A 98	None	0.76A	3qxvC-4qlrA: 22.5	3qxvC-4qlrA: 69.84
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4qo1	NB139 NANOBODY AGAINST THE DNA-BINDING DOMAIN OF P53 (Lama glama)	PF07686 (V-set)	6	ALA A 25 MET A 35 ARG A 73 ASN A 75 VAL A 80 ALA A 99	None	0.58A	3qxvC-4qo1A: 21.5	3qxvC-4qo1A: 62.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4tvs	VHH DOMAIN BS-1 (Vicugna pacos)	PF05609 (LAP1C)	5	ALA a 25 ARG a 73 ASN a 75 VAL a 80 ALA a 99	None	0.81A	3qxvC-4tvsa: 22.6	3qxvC-4tvsa: 72.87
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ut6	BROADLY NEUTRALIZING HUMAN ANTIBODY EDE2 B7 (Homo sapiens)	PF07686 (V-set)	5	VAL H 2 MET H 34 ARG H 71 ASN H 73 VAL H 78	None	0.77A	3qxvC-4ut6H: 18.9	3qxvC-4ut6H: 57.04
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4w6y	NANOBODY NBFEDF9 (Lama glama)	PF07686 (V-set)	6	VAL B 2 ALA B 24 MET B 34 ASN B 74 VAL B 79 ALA B 98	None None None SO4 B 201 (-4.0A) None None	0.97A	3qxvC-4w6yB: 21.3	3qxvC-4w6yB: 69.47
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4weu	ANTI-F4+ETEC BACTERIA VHH VARIABLE REGION (Lama glama)	PF07686 (V-set)	6	VAL D 802 ALA D 824 MET D 834 ARG D 872 ASN D 874 ALA D 898	None	0.70A	3qxvC-4weuD: 22.4	3qxvC-4weuD: 72.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4xt1	NANOBODY 7 (Vicugna pacos)	PF07686 (V-set)	6	VAL C 2 ALA C 24 MET C 34 ASN C 73 VAL C 78 ALA C 97	None	0.89A	3qxvC-4xt1C: 19.3	3qxvC-4xt1C: 68.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4y5v	DIABODY 305 VH DOMAIN (Homo sapiens)	PF07686 (V-set)	5	VAL A 2 MET A 34 ARG A 72 ASN A 74 VAL A 79	None	0.53A	3qxvC-4y5vA: 21.1	3qxvC-4y5vA: 66.67
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ybq	ANTIBODY FV FRAGMENT HEAVY CHAIN (Mus musculus)	PF07686 (V-set)	5	VAL D 3 ALA D 25 MET D 35 ARG D 73 ASN D 75	None	0.80A	3qxvC-4ybqD: 21.2	3qxvC-4ybqD: 58.73
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4ydv	HIV ANTIBODY 7B2 HEAVY CHAIN,IGG H CHAIN (Homo sapiens)	no annotation	5	VAL H 2 MET H 34 ARG H 71 ASN H 72 VAL H 75	None	0.66A	3qxvC-4ydvH: 19.3	3qxvC-4ydvH: 37.56
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4yga	VHH-1B7 (Vicugna pacos)	PF07686 (V-set)	6	VAL B 3 ALA B 25 ARG B 73 ASN B 75 VAL B 80 ALA B 99	None	0.72A	3qxvC-4ygaB: 20.5	3qxvC-4ygaB: 60.32
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5aum	HEAVY CHAIN OF FAB FRAGMENT (Rattus)	no annotation	6	VAL H 2 ALA H 24 MET H 34 ARG H 71 VAL H 78 ALA H 94	None	0.70A	3qxvC-5aumH: 20.0	3qxvC-5aumH: 38.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5b6f	ANTI-LEUKOTRIENE C4 MONOCLONAL ANTIBODY IMMUNOGLOBULIN GAMMA1 HEAVY CHAIN (Mus musculus)	PF07654 (C1-set) PF07686 (V-set)	5	VAL B 21 ALA B 43 MET B 53 ARG B 93 VAL B 100	None	0.80A	3qxvC-5b6fB: 19.5	3qxvC-5b6fB: 35.07
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5bop	NANOBODY (Lama glama)	PF07686 (V-set)	5	MET A 34 ARG A 72 ASN A 74 VAL A 79 ALA A 98	None	0.53A	3qxvC-5bopA: 22.6	3qxvC-5bopA: 69.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5drz	HIV ANTIBODY F240 HEAVY CHAIN (Homo sapiens)	no annotation	5	VAL H 2 MET H 34 ARG H 71 ASN H 73 VAL H 78	None	0.56A	3qxvC-5drzH: 18.9	3qxvC-5drzH: 55.20
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5dxw	PD-L1 NANOBODY (Mus musculus)	PF07686 (V-set)	5	VAL A 4 MET A 36 ARG A 74 ASN A 76 VAL A 81	None	0.74A	3qxvC-5dxwA: 20.7	3qxvC-5dxwA: 65.08
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5e1h	F8(JOB10) VHH ANTIBODY (Vicugna pacos)	PF07686 (V-set)	6	VAL B 2 ALA B 24 MET B 34 ARG B 72 ASN B 74 VAL B 79	None	0.93A	3qxvC-5e1hB: 20.8	3qxvC-5e1hB: 68.75
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5e7f	NANOBODY L06 (Camelus dromedarius)	PF07686 (V-set)	6	VAL A 4 ALA A 26 ARG A 73 ASN A 75 VAL A 80 ALA A 99	None	0.88A	3qxvC-5e7fA: 18.6	3qxvC-5e7fA: 66.93
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5e7f	NANOBODY L06 (Camelus dromedarius)	PF07686 (V-set)	6	VAL A 4 MET A 36 ARG A 73 ASN A 75 VAL A 80 ALA A 99	None	0.64A	3qxvC-5e7fA: 18.6	3qxvC-5e7fA: 66.93
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5f1k	NANOBODY MU1053 (Lama glama)	PF07686 (V-set)	5	MET C 34 ARG C 72 ASN C 74 VAL C 79 ALA C 98	None	0.46A	3qxvC-5f1kC: 22.3	3qxvC-5f1kC: 67.46
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5f1o	NANOBODY MU551 (Lama glama)	PF07686 (V-set)	5	MET B 34 ARG B 72 ASN B 74 VAL B 79 ALA B 98	None	0.39A	3qxvC-5f1oB: 21.5	3qxvC-5f1oB: 65.91
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5fhc	ANTIBODY 114 FAB HEAVY CHAIN (Homo sapiens)	PF07654 (C1-set) PF07686 (V-set)	5	VAL H 2 ALA H 24 MET H 34 ARG H 71 ASN H 73	None	0.81A	3qxvC-5fhcH: 20.4	3qxvC-5fhcH: 37.88
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5fwo	NANOBODY (Lama glama)	PF07686 (V-set)	7	VAL A 2 ALA A 24 MET A 34 ARG A 71 ASN A 73 VAL A 78 ALA A 94	None	0.81A	3qxvC-5fwoA: 21.8	3qxvC-5fwoA: 68.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5gxb	NANOBODY (Vicugna pacos)	PF07686 (V-set)	6	VAL B 2 ALA B 24 MET B 34 ASN B 74 VAL B 79 ALA B 98	None	0.89A	3qxvC-5gxbB: 21.0	3qxvC-5gxbB: 68.42
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5hvf	VHH-I83 (Vicugna pacos)	PF07686 (V-set)	6	VAL B 2 ALA B 24 MET B 34 ASN B 72 VAL B 77 ALA B 96	None	1.15A	3qxvC-5hvfB: 18.9	3qxvC-5hvfB: 69.35
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5iml	NANOBODY (Camelidae)	PF07686 (V-set)	6	ALA B 23 MET B 33 ARG B 71 ASN B 73 VAL B 78 ALA B 97	None	0.72A	3qxvC-5imlB: 24.1	3qxvC-5imlB: 75.40
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5j1s	VHH DOMAIN BS-2 (Vicugna pacos)	PF07686 (V-set)	6	ALA C 25 MET C 35 ARG C 72 ASN C 74 VAL C 79 ALA C 98	None	0.90A	3qxvC-5j1sC: 19.7	3qxvC-5j1sC: 66.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5j1s	VHH DOMAIN BS-2 (Vicugna pacos)	PF07686 (V-set)	5	VAL C 3 ALA C 25 MET C 35 VAL C 79 ALA C 98	None	0.72A	3qxvC-5j1sC: 19.7	3qxvC-5j1sC: 66.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5j57	VHH SINGLE CHAIN ANTIBODY V5E1 (Vicugna pacos)	PF07686 (V-set)	5	ALA B 24 ARG B 72 ASN B 74 VAL B 79 ALA B 98	None	0.44A	3qxvC-5j57B: 20.9	3qxvC-5j57B: 65.60
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5ja8	NANOBODY 2 (Lama glama)	PF07686 (V-set)	6	VAL B 3 ALA B 25 ARG B 73 ASN B 75 VAL B 80 ALA B 99	None	0.66A	3qxvC-5ja8B: 20.4	3qxvC-5ja8B: 70.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5ja9	NANOBODY 6 (Lama glama)	PF07686 (V-set)	6	VAL A 3 ALA A 25 MET A 35 ARG A 73 ASN A 75 ALA A 99	None	0.89A	3qxvC-5ja9A: 20.4	3qxvC-5ja9A: 68.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5jmo	CAMELID VHH FRAGMENT (Camelus dromedarius)	PF07686 (V-set)	5	VAL C 2 ALA C 24 MET C 34 ARG C 72 ASN C 74	None	0.80A	3qxvC-5jmoC: 20.2	3qxvC-5jmoC: 63.71
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5jqh	NANOBODY60, NB60 (Lama glama)	no annotation	5	MET D 34 ARG D 71 ASN D 73 VAL D 78 ALA D 97	None	0.75A	3qxvC-5jqhD: 19.5	3qxvC-5jqhD: 70.16
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5lhq	CAMELID-DERIVED ANTIBODY FRAGMENT NB7 (Vicugna pacos)	PF07686 (V-set)	6	VAL B 2 ALA B 24 ARG B 72 ASN B 74 VAL B 79 ALA B 98	None	0.57A	3qxvC-5lhqB: 21.9	3qxvC-5lhqB: 64.66
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5lhr	CAMELID-DERIVED ANTIBODY FRAGMENT NB22 (Vicugna pacos)	PF07686 (V-set)	6	ALA B 24 MET B 34 ARG B 72 ASN B 74 VAL B 79 ALA B 98	None	0.89A	3qxvC-5lhrB: 20.2	3qxvC-5lhrB: 76.00
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5lmj	NANOBODY (Lama glama)	PF07686 (V-set)	6	ALA A 24 MET A 34 ARG A 71 ASN A 73 VAL A 78 ALA A 94	None	0.93A	3qxvC-5lmjA: 20.4	3qxvC-5lmjA: 73.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5lmj	NANOBODY (Lama glama)	PF07686 (V-set)	6	VAL A 2 ALA A 24 ARG A 71 ASN A 73 VAL A 78 ALA A 94	None	0.84A	3qxvC-5lmjA: 20.4	3qxvC-5lmjA: 73.23
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5lwf	CAMELID HEAVY-CHAIN ANTIBODY VARIABLE FRAGMENT CAB-G10S (Lama glama)	no annotation	7	VAL C 5 ALA C 27 MET C 37 ARG C 75 ASN C 77 VAL C 82 ALA C 101	None	0.70A	3qxvC-5lwfC: 21.5	3qxvC-5lwfC: 68.80
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5mwn	LLAMA NANOBODY RAISED AGAINST TSSK, NBK27 (Lama glama)	PF07686 (V-set)	5	VAL N 2 ALA N 24 MET N 34 VAL N 78 ALA N 97	None	0.78A	3qxvC-5mwnN: 18.2	3qxvC-5mwnN: 67.46
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5o02	NANOBODY (VHH) NANO-4 (Vicugna pacos)	PF07686 (V-set)	5	VAL C 2 MET C 34 ARG C 72 ASN C 74 ALA C 98	None	0.47A	3qxvC-5o02C: 21.6	3qxvC-5o02C: 68.55
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5o04	NANOBODY (VHH) NANO-26 (Vicugna pacos)	PF07686 (V-set)	5	VAL E 2 ALA E 24 ARG E 71 ASN E 73 VAL E 78	None	0.66A	3qxvC-5o04E: 18.8	3qxvC-5o04E: 65.32
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5o8f	NANOBODY NB25 (Lama glama)	no annotation	5	MET L 34 ARG L 72 ASN L 74 VAL L 79 ALA L 98	None	0.44A	3qxvC-5o8fL: 21.7	3qxvC-5o8fL: 68.46
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5omn	NANOBODY (VHH) NANO-27 (Vicugna pacos)	PF07686 (V-set)	5	VAL C 2 ALA C 24 MET C 34 ARG C 71 ASN C 73	None	0.77A	3qxvC-5omnC: 19.7	3qxvC-5omnC: 65.32
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5ovw	NANOBODY (Lama glama)	no annotation	5	ALA G 46 ARG G 94 ASN G 96 VAL G 101 ALA G 120	None	0.44A	3qxvC-5ovwG: 21.7	3qxvC-5ovwG: 59.57
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5tr8	441D6 FAB HEAVY CHAIN (Mus musculus)	no annotation	5	VAL H 2 ALA H 24 MET H 34 ARG H 71 ASN H 73	None	0.80A	3qxvC-5tr8H: 19.1	3qxvC-5tr8H: 54.88
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5u68	MPE8 (Homo sapiens)	PF07686 (V-set)	5	VAL E 21 ALA E 43 MET E 53 ARG E 91 ASN E 93	None	0.80A	3qxvC-5u68E: 21.0	3qxvC-5u68E: 61.72
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5uk4	ANTI-VESICULAR STOMATITIS VIRUS N VHH (Vicugna pacos)	no annotation	6	VAL p 2 MET p 34 ARG p 72 ASN p 74 VAL p 79 ALA p 98	None	0.69A	3qxvC-5uk4p: 21.6	3qxvC-5uk4p: 71.43
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5vaq	NB914 (Lama glama)	no annotation	6	ALA B 24 SER B 30 ARG B 72 ASN B 74 VAL B 79 ALA B 98	None	0.98A	3qxvC-5vaqB: 23.3	3qxvC-5vaqB: 75.00
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5vf6	SINGLE CHAIN VARIABLE FRAGMENT (Gallus gallus)	no annotation	6	VAL A 125 ALA A 147 MET A 157 ARG A 195 ASN A 197 VAL A 202	None	0.97A	3qxvC-5vf6A: 20.4	3qxvC-5vf6A: 21.09
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5vk2	FAB 37.7H HEAVY CHAIN (Homo sapiens)	PF07654 (C1-set) PF07686 (V-set)	5	VAL D 3 ALA D 25 MET D 35 ARG D 74 ASN D 76	None	0.79A	3qxvC-5vk2D: 20.5	3qxvC-5vk2D: 40.70
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5vxj	SINGLE-DOMAIN ANTIBODY JMK-E3 (Vicugna pacos)	no annotation	6	VAL B 2 MET B 34 ARG B 72 ASN B 74 VAL B 79 ALA B 98	None	0.71A	3qxvC-5vxjB: 19.5	3qxvC-5vxjB: 63.08
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5vxl	SINGLE-DOMAIN ANTIBODY JPS-G3 (Vicugna pacos)	no annotation	6	ALA B 24 MET B 34 ARG B 73 ASN B 75 VAL B 80 ALA B 99	None	0.74A	3qxvC-5vxlB: 20.3	3qxvC-5vxlB: 66.41
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5vxm	SINGLE-DOMAIN ANTIBODY 20IPAD (Vicugna pacos)	no annotation	5	VAL B 2 ARG B 72 ASN B 74 VAL B 79 ALA B 98	None	0.70A	3qxvC-5vxmB: 23.0	3qxvC-5vxmB: 70.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5wb1	ENVELOPE PROTEIN US28, NANOBODY 7 FUSION PROTEIN (Human betaherpesvirus 5; Lama glama)	no annotation	6	VAL A1002 ALA A1024 MET A1034 ASN A1073 VAL A1078 ALA A1097	None	0.94A	3qxvC-5wb1A: 18.3	3qxvC-5wb1A: 15.08
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5xaj	FABHM14C10 HEAVY CHAIN (Homo sapiens)	PF07654 (C1-set) PF07686 (V-set)	5	VAL A 2 ALA A 24 MET A 34 ASN A 74 VAL A 79	None	0.78A	3qxvC-5xajA: 21.2	3qxvC-5xajA: 64.29
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5y9f	HEAVY CHAIN OF FAB FRAGMENT OF ANTIBODY 28F10 (Mus musculus)	no annotation	5	VAL L 2 ALA L 24 MET L 34 ARG L 72 ASN L 74	None	0.74A	3qxvC-5y9fL: 20.3	3qxvC-5y9fL: 57.94
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5yy5	- (-)	no annotation	5	VAL C 2 ALA C 24 MET C 34 ARG C 71 ASN C 73	None	0.69A	3qxvC-5yy5C: 19.6	3qxvC-5yy5C: undetectable
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6d11	1450 ANTIBODY, HEAVY CHAIN (Homo sapiens)	no annotation	5	VAL A 2 MET A 34 ARG A 71 ASN A 73 VAL A 78	None	0.55A	3qxvC-6d11A: 20.1	3qxvC-6d11A: 44.72
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6ehg	HC3NB1 (Lama glama)	no annotation	6	ALA C 24 MET C 34 ARG C 72 ASN C 74 VAL C 79 ALA C 98	None	0.70A	3qxvC-6ehgC: 22.4	3qxvC-6ehgC: 57.14
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	6fe4	NB113 (Vicugna pacos)	no annotation	5	VAL F 2 ALA F 24 MET F 34 ARG F 72 ASN F 74	None	0.81A	3qxvC-6fe4F: 20.8	3qxvC-6fe4F: 66.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6gzp	NANOBODY (Lama glama)	no annotation	6	VAL A 2 ALA A 24 MET A 34 ARG A 71 ASN A 73 ALA A 94	None	0.71A	3qxvC-6gzpA: 22.0	3qxvC-6gzpA: undetectable
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	8fab	IGG1-LAMBDA HIL FAB (HEAVY CHAIN) (Homo sapiens)	PF07654 (C1-set) PF07686 (V-set)	5	VAL B 2 ALA B 24 MET B 34 ARG B 72 ASN B 74	None	0.79A	3qxvC-8fabB: 22.0	3qxvC-8fabB: 59.52

[["3QXV_C_MTXC2000_1","1kxt","Camelus dromedarius","IMMUNOGLOBULIN VHH FRAGMENT","PF07686(V-set)",6,"VAL B   2;ALA B  24;MET B  34;ARG B  71;ASN B  73;ALA B  94","None","0.97A","3qxvC-1kxtB:19.5","3qxvC-1kxtB:68.75"],["3QXV_C_MTXC2000_1","1pz5","Mus musculus","HEAVY CHAIN OF FAB (SYA\/J6)","PF07654(C1-set);PF07686(V-set)",5,"VAL B   2;ALA B  24;MET B  34;ARG B  71;VAL B  78","None","0.83A","3qxvC-1pz5B:20.2","3qxvC-1pz5B:51.52"],["3QXV_C_MTXC2000_1","2aeq","Mus musculus","FAB HEAVY CHAIN","PF07686(V-set)",5,"VAL H   2;MET H  34;ARG H  74;ASN H  76;VAL H  81","None","0.82A","3qxvC-2aeqH:18.2","3qxvC-2aeqH:33.96"],["3QXV_C_MTXC2000_1","2fl5","Homo sapiens","IMMUNOGLOBULIN IGG1 HEAVY CHAIN","no annotation",5,"VAL H   2;ALA H  24;MET H  34;ARG H  71;ASN H  73","None","0.77A","3qxvC-2fl5H:20.8","3qxvC-2fl5H:35.50"],["3QXV_C_MTXC2000_1","2jgv","Staphylococcus aureus","TAGATOSE-6-PHOSPHATE KINASE","PF00294(PfkB)",6,"VAL A 239;ALA A 230;ARG A 238;SER A 222;VAL A 181;ALA A 277","None","1.08A","3qxvC-2jgvA:undetectable","3qxvC-2jgvA:16.87"],["3QXV_C_MTXC2000_1","2uzi","Homo sapiens","ANTI-RAS FV HEAVY CHAIN","PF07686(V-set)",5,"VAL H   2;ALA H  24;MET H  34;ARG H  72;ASN H  74","None","0.79A","3qxvC-2uziH:21.4","3qxvC-2uziH:60.00"],["3QXV_C_MTXC2000_1","2xa3","Lama glama","LLAMA HEAVY CHAIN ANTIBODY D7","PF07686(V-set)",5,"SER A  29;MET A  34;ASN A  73;VAL A  78;ALA A  94","SO4 A1114 (-2.7A);None;None;None;None","0.80A","3qxvC-2xa3A:21.2","3qxvC-2xa3A:69.77"],["3QXV_C_MTXC2000_1","3g9a","Camelus dromedarius","MINIMIZER","PF07686(V-set)",5,"ALA B  24;MET B  34;ARG B  71;VAL B  78;ALA B  94","None","0.71A","3qxvC-3g9aB:20.0","3qxvC-3g9aB:64.93"],["3QXV_C_MTXC2000_1","3k7u","Lama glama","ANTIBODY","PF07686(V-set)",5,"MET A  34;ARG A  72;ASN A  74;VAL A  79;ALA A  98","None","0.28A","3qxvC-3k7uA:22.1","3qxvC-3k7uA:73.81"],["3QXV_C_MTXC2000_1","3ln9","Camelidae","IMMUNOGLOBULIN HEAVY CHAIN ANTIBODY VARIABLE DOMAIN B10","PF07686(V-set)",6,"VAL A   2;ALA A  24;ARG A  72;ASN A  74;VAL A  79;ALA A  98","None","0.85A","3qxvC-3ln9A:19.7","3qxvC-3ln9A:67.94"],["3QXV_C_MTXC2000_1","3piq","Homo sapiens","HUMAN MONOCLONAL ANTIBODY 2909 FAB HEAVY CHAIN","no annotation",5,"VAL H   2;ALA H  24;MET H  34;ARG H  71;ASN H  73","None","0.80A","3qxvC-3piqH:19.6","3qxvC-3piqH:56.82"],["3QXV_C_MTXC2000_1","3qxu","Lama glama","ANTI-METHOTREXATE CDR1-3 GRAFT","PF07686(V-set)",7,"VAL A   4;ALA A  26;SER A  30;MET A  36;ARG A  74;VAL A  81;ALA A 100","None","0.89A","3qxvC-3qxuA:24.5","3qxvC-3qxuA:96.03"],["3QXV_C_MTXC2000_1","3qyc","Homo sapiens","VH DOMAIN OF IGG MOLECULE","PF07686(V-set)",5,"ALA A  26;MET A  36;ARG A  74;ASN A  76;VAL A  81","None","0.73A","3qxvC-3qycA:20.1","3qxvC-3qycA:61.42"],["3QXV_C_MTXC2000_1","3qyc","Homo sapiens","VH DOMAIN OF IGG MOLECULE","PF07686(V-set)",5,"VAL A   4;ALA A  26;MET A  36;ARG A  74;VAL A  81","None","0.83A","3qxvC-3qycA:20.1","3qxvC-3qycA:61.42"],["3QXV_C_MTXC2000_1","3r0m","Lama glama","LLAMA VHH A12","PF07686(V-set)",6,"ALA A  24;SER A  29;MET A  34;ASN A  73;VAL A  78;ALA A  94","None;SO4 A 131 (-2.7A);None;None;None;None","1.12A","3qxvC-3r0mA:21.2","3qxvC-3r0mA:70.54"],["3QXV_C_MTXC2000_1","3stb","Lama glama","SINGLE DOMAIN ANTIBODY VHH","PF07686(V-set)",6,"ALA A  26;MET A  36;ARG A  73;ASN A  75;VAL A  80;ALA A  99","None","0.71A","3qxvC-3stbA:22.5","3qxvC-3stbA:70.77"],["3QXV_C_MTXC2000_1","4dgy","Homo sapiens","HCV1 HEAVY CHAIN","PF07654(C1-set);PF07686(V-set)",5,"VAL H   2;ALA H  24;MET H  34;ARG H  71;ASN H  73","GOL H 302 (-4.1A);None;None;None;None","0.80A","3qxvC-4dgyH:20.6","3qxvC-4dgyH:37.19"],["3QXV_C_MTXC2000_1","4dka","Lama glama","SINGLE DOMAIN ANTIBODY VHH","PF07686(V-set)",6,"ALA A  24;MET A  34;ARG A  72;ASN A  74;VAL A  79;ALA A  98","None","0.78A","3qxvC-4dkaA:22.3","3qxvC-4dkaA:73.23"],["3QXV_C_MTXC2000_1","4eig","Lama glama","CA1698 CAMEL ANTIBODY FRAGMENT","PF07686(V-set)",6,"ALA B  24;MET B  34;ARG B  71;ASN B  73;VAL B  78;ALA B  97","None","0.75A","3qxvC-4eigB:20.5","3qxvC-4eigB:66.94"],["3QXV_C_MTXC2000_1","4ej1","Lama glama","NB113 CAMELID ANTIBODY FRAGMENT","PF07686(V-set)",5,"ALA C  24;MET C  34;ASN C  74;VAL C  79;ALA C  98","None","0.70A","3qxvC-4ej1C:21.7","3qxvC-4ej1C:74.22"],["3QXV_C_MTXC2000_1","4ej1","Lama glama","NB113 CAMELID ANTIBODY FRAGMENT","PF07686(V-set)",5,"MET C  34;ARG C  72;ASN C  74;VAL C  79;ALA C  98","None","0.38A","3qxvC-4ej1C:21.7","3qxvC-4ej1C:74.22"],["3QXV_C_MTXC2000_1","4fhb","Lama glama","NB179","PF07686(V-set)",5,"MET D  34;ARG D  72;ASN D  74;VAL D  79;ALA D  98","None","0.50A","3qxvC-4fhbD:21.4","3qxvC-4fhbD:71.32"],["3QXV_C_MTXC2000_1","4fql","Homo sapiens","MONOCLONAL ANTIBODY CR8033 HEAVY CHAIN","PF07654(C1-set);PF07686(V-set)",5,"VAL H   2;ALA H  24;MET H  34;ARG H  71;ASN H  73","None","0.75A","3qxvC-4fqlH:21.7","3qxvC-4fqlH:59.69"],["3QXV_C_MTXC2000_1","4gft","Lama glama","NANOBODY","PF07686(V-set)",5,"MET B  36;ARG B  74;ASN B  76;VAL B  81;ALA B 100","None","0.26A","3qxvC-4gftB:22.7","3qxvC-4gftB:66.93"],["3QXV_C_MTXC2000_1","4glr","Gallus gallus","ANTI-PTAU HEAVY CHAIN","PF07654(C1-set);PF07686(V-set)",5,"VAL H   2;MET H  34;ARG H  71;ASN H  73;VAL H  78","None","0.60A","3qxvC-4glrH:21.1","3qxvC-4glrH:30.30"],["3QXV_C_MTXC2000_1","4hem","Lama glama","ANTI-BASEPLATE TP901-1 LLAMA VHH 02","PF07686(V-set)",6,"ALA E  24;MET E  34;ARG E  72;ASN E  74;VAL E  79;ALA E  98","None","0.68A","3qxvC-4hemE:23.2","3qxvC-4hemE:73.39"],["3QXV_C_MTXC2000_1","4kfz","Homo sapiens","ANTI-LMO2 VH","PF07686(V-set)",6,"VAL C   2;ALA C  24;SER C  28;MET C  34;ARG C  72;ASN C  74","None","0.90A","3qxvC-4kfzC:20.1","3qxvC-4kfzC:61.83"],["3QXV_C_MTXC2000_1","4krm","Lama glama","NANOBODY\/VHH DOMAIN 7D12","PF07686(V-set)",5,"ALA B  24;MET B  34;ARG B  72;VAL B  79;ALA B  98","None","0.70A","3qxvC-4krmB:23.8","3qxvC-4krmB:70.16"],["3QXV_C_MTXC2000_1","4krm","Lama glama","NANOBODY\/VHH DOMAIN 7D12","PF07686(V-set)",5,"MET B  34;ARG B  72;ASN B  74;VAL B  79;ALA B  98","None","0.34A","3qxvC-4krmB:23.8","3qxvC-4krmB:70.16"],["3QXV_C_MTXC2000_1","4lhq","Vicugna pacos","CAMELID NANOBODY","PF07686(V-set)",5,"SER B  28;MET B  34;ARG B  72;ASN B  74;VAL B  79","None","0.64A","3qxvC-4lhqB:22.0","3qxvC-4lhqB:63.28"],["3QXV_C_MTXC2000_1","4n1h","Lama glama","CAMELID HEAVY-CHAIN ANTIBODY VARIABLE FRAGMENT CAB-F11N","PF07686(V-set)",5,"ALA B  24;MET B  34;ASN B  74;VAL B  79;ALA B  98","None","0.69A","3qxvC-4n1hB:21.6","3qxvC-4n1hB:68.50"],["3QXV_C_MTXC2000_1","4n1h","Lama glama","CAMELID HEAVY-CHAIN ANTIBODY VARIABLE FRAGMENT CAB-F11N","PF07686(V-set)",5,"MET B  34;ARG B  72;ASN B  74;VAL B  79;ALA B  98","None","0.44A","3qxvC-4n1hB:21.6","3qxvC-4n1hB:68.50"],["3QXV_C_MTXC2000_1","4nc1","Lama glama","A20.1 VHH","PF07686(V-set)",7,"VAL C   9;ALA C  31;MET C  41;ARG C  79;ASN C  81;VAL C  86;ALA C 105","None","0.93A","3qxvC-4nc1C:22.2","3qxvC-4nc1C:70.23"],["3QXV_C_MTXC2000_1","4nc2","Lama glama","B39 VHH","PF07686(V-set)",6,"VAL B   2;ALA B  24;MET B  34;ARG B  71;ASN B  73;ALA B  97","None","0.73A","3qxvC-4nc2B:23.2","3qxvC-4nc2B:70.16"],["3QXV_C_MTXC2000_1","4ocr","Homo sapiens","CAP256-VRC26.01 HEAVY CHAIN","PF07654(C1-set);PF07686(V-set)",5,"VAL H   2;MET H  34;ARG H  71;ASN H  73;VAL H  78","None","0.53A","3qxvC-4ocrH:21.7","3qxvC-4ocrH:54.05"],["3QXV_C_MTXC2000_1","4ouo","Gallus gallus","ANTI BLA G 1 SCFV","PF07686(V-set)",6,"VAL A 116;ALA A 138;MET A 148;ARG A 185;ASN A 187;VAL A 192","None","0.90A","3qxvC-4ouoA:20.9","3qxvC-4ouoA:27.27"],["3QXV_C_MTXC2000_1","4p2c","Lama glama","NANOBODY 1, ANTI-F4+ETEC BACTERIA VHH VARIABLE REGION","PF07686(V-set)",6,"VAL G   2;MET G  34;ARG G  71;ASN G  73;VAL G  78;ALA G  97","None","0.57A","3qxvC-4p2cG:19.1","3qxvC-4p2cG:70.97"],["3QXV_C_MTXC2000_1","4p49","Gallus gallus","ANTIBODY SCFV B8","PF07686(V-set)",6,"VAL A 122;ALA A 144;MET A 154;ARG A 193;ASN A 195;VAL A 200","None","0.93A","3qxvC-4p49A:22.0","3qxvC-4p49A:51.88"],["3QXV_C_MTXC2000_1","4qlr","Lama glama","LLAMA NANOBODY N02 VH DOMAIN","PF07686(V-set)",5,"ALA A  24;ARG A  72;ASN A  74;VAL A  79;ALA A  98","None","0.76A","3qxvC-4qlrA:22.5","3qxvC-4qlrA:69.84"],["3QXV_C_MTXC2000_1","4qo1","Lama glama","NB139 NANOBODY AGAINST THE DNA-BINDING DOMAIN OF P53","PF07686(V-set)",6,"ALA A  25;MET A  35;ARG A  73;ASN A  75;VAL A  80;ALA A  99","None","0.58A","3qxvC-4qo1A:21.5","3qxvC-4qo1A:62.70"],["3QXV_C_MTXC2000_1","4tvs","Vicugna pacos","VHH DOMAIN BS-1","PF05609(LAP1C)",5,"ALA a  25;ARG a  73;ASN a  75;VAL a  80;ALA a  99","None","0.81A","3qxvC-4tvsa:22.6","3qxvC-4tvsa:72.87"],["3QXV_C_MTXC2000_1","4ut6","Homo sapiens","BROADLY NEUTRALIZING HUMAN ANTIBODY EDE2 B7","PF07686(V-set)",5,"VAL H   2;MET H  34;ARG H  71;ASN H  73;VAL H  78","None","0.77A","3qxvC-4ut6H:18.9","3qxvC-4ut6H:57.04"],["3QXV_C_MTXC2000_1","4w6y","Lama glama","NANOBODY NBFEDF9","PF07686(V-set)",6,"VAL B   2;ALA B  24;MET B  34;ASN B  74;VAL B  79;ALA B  98","None;None;None;SO4 B 201 (-4.0A);None;None","0.97A","3qxvC-4w6yB:21.3","3qxvC-4w6yB:69.47"],["3QXV_C_MTXC2000_1","4weu","Lama glama","ANTI-F4+ETEC BACTERIA VHH VARIABLE REGION","PF07686(V-set)",6,"VAL D 802;ALA D 824;MET D 834;ARG D 872;ASN D 874;ALA D 898","None","0.70A","3qxvC-4weuD:22.4","3qxvC-4weuD:72.00"],["3QXV_C_MTXC2000_1","4xt1","Vicugna pacos","NANOBODY 7","PF07686(V-set)",6,"VAL C   2;ALA C  24;MET C  34;ASN C  73;VAL C  78;ALA C  97","None","0.89A","3qxvC-4xt1C:19.3","3qxvC-4xt1C:68.75"],["3QXV_C_MTXC2000_1","4y5v","Homo sapiens","DIABODY 305 VH DOMAIN","PF07686(V-set)",5,"VAL A   2;MET A  34;ARG A  72;ASN A  74;VAL A  79","None","0.53A","3qxvC-4y5vA:21.1","3qxvC-4y5vA:66.67"],["3QXV_C_MTXC2000_1","4ybq","Mus musculus","ANTIBODY FV FRAGMENT HEAVY CHAIN","PF07686(V-set)",5,"VAL D   3;ALA D  25;MET D  35;ARG D  73;ASN D  75","None","0.80A","3qxvC-4ybqD:21.2","3qxvC-4ybqD:58.73"],["3QXV_C_MTXC2000_1","4ydv","Homo sapiens","HIV ANTIBODY 7B2 HEAVY CHAIN,IGG H CHAIN","no annotation",5,"VAL H   2;MET H  34;ARG H  71;ASN H  72;VAL H  75","None","0.66A","3qxvC-4ydvH:19.3","3qxvC-4ydvH:37.56"],["3QXV_C_MTXC2000_1","4yga","Vicugna pacos","VHH-1B7","PF07686(V-set)",6,"VAL B   3;ALA B  25;ARG B  73;ASN B  75;VAL B  80;ALA B  99","None","0.72A","3qxvC-4ygaB:20.5","3qxvC-4ygaB:60.32"],["3QXV_C_MTXC2000_1","5aum","Rattus","HEAVY CHAIN OF FAB FRAGMENT","no annotation",6,"VAL H   2;ALA H  24;MET H  34;ARG H  71;VAL H  78;ALA H  94","None","0.70A","3qxvC-5aumH:20.0","3qxvC-5aumH:38.16"],["3QXV_C_MTXC2000_1","5b6f","Mus musculus","ANTI-LEUKOTRIENE C4 MONOCLONAL ANTIBODY IMMUNOGLOBULIN GAMMA1 HEAVY CHAIN","PF07654(C1-set);PF07686(V-set)",5,"VAL B  21;ALA B  43;MET B  53;ARG B  93;VAL B 100","None","0.80A","3qxvC-5b6fB:19.5","3qxvC-5b6fB:35.07"],["3QXV_C_MTXC2000_1","5bop","Lama glama","NANOBODY","PF07686(V-set)",5,"MET A  34;ARG A  72;ASN A  74;VAL A  79;ALA A  98","None","0.53A","3qxvC-5bopA:22.6","3qxvC-5bopA:69.60"],["3QXV_C_MTXC2000_1","5drz","Homo sapiens","HIV ANTIBODY F240 HEAVY CHAIN","no annotation",5,"VAL H   2;MET H  34;ARG H  71;ASN H  73;VAL H  78","None","0.56A","3qxvC-5drzH:18.9","3qxvC-5drzH:55.20"],["3QXV_C_MTXC2000_1","5dxw","Mus musculus","PD-L1 NANOBODY","PF07686(V-set)",5,"VAL A   4;MET A  36;ARG A  74;ASN A  76;VAL A  81","None","0.74A","3qxvC-5dxwA:20.7","3qxvC-5dxwA:65.08"],["3QXV_C_MTXC2000_1","5e1h","Vicugna pacos","F8(JOB10) VHH ANTIBODY","PF07686(V-set)",6,"VAL B   2;ALA B  24;MET B  34;ARG B  72;ASN B  74;VAL B  79","None","0.93A","3qxvC-5e1hB:20.8","3qxvC-5e1hB:68.75"],["3QXV_C_MTXC2000_1","5e7f","Camelus dromedarius","NANOBODY L06","PF07686(V-set)",6,"VAL A   4;ALA A  26;ARG A  73;ASN A  75;VAL A  80;ALA A  99","None","0.88A","3qxvC-5e7fA:18.6","3qxvC-5e7fA:66.93"],["3QXV_C_MTXC2000_1","5e7f","Camelus dromedarius","NANOBODY L06","PF07686(V-set)",6,"VAL A   4;MET A  36;ARG A  73;ASN A  75;VAL A  80;ALA A  99","None","0.64A","3qxvC-5e7fA:18.6","3qxvC-5e7fA:66.93"],["3QXV_C_MTXC2000_1","5f1k","Lama glama","NANOBODY MU1053","PF07686(V-set)",5,"MET C  34;ARG C  72;ASN C  74;VAL C  79;ALA C  98","None","0.46A","3qxvC-5f1kC:22.3","3qxvC-5f1kC:67.46"],["3QXV_C_MTXC2000_1","5f1o","Lama glama","NANOBODY MU551","PF07686(V-set)",5,"MET B  34;ARG B  72;ASN B  74;VAL B  79;ALA B  98","None","0.39A","3qxvC-5f1oB:21.5","3qxvC-5f1oB:65.91"],["3QXV_C_MTXC2000_1","5fhc","Homo sapiens","ANTIBODY 114 FAB HEAVY CHAIN","PF07654(C1-set);PF07686(V-set)",5,"VAL H   2;ALA H  24;MET H  34;ARG H  71;ASN H  73","None","0.81A","3qxvC-5fhcH:20.4","3qxvC-5fhcH:37.88"],["3QXV_C_MTXC2000_1","5fwo","Lama glama","NANOBODY","PF07686(V-set)",7,"VAL A   2;ALA A  24;MET A  34;ARG A  71;ASN A  73;VAL A  78;ALA A  94","None","0.81A","3qxvC-5fwoA:21.8","3qxvC-5fwoA:68.18"],["3QXV_C_MTXC2000_1","5gxb","Vicugna pacos","NANOBODY","PF07686(V-set)",6,"VAL B   2;ALA B  24;MET B  34;ASN B  74;VAL B  79;ALA B  98","None","0.89A","3qxvC-5gxbB:21.0","3qxvC-5gxbB:68.42"],["3QXV_C_MTXC2000_1","5hvf","Vicugna pacos","VHH-I83","PF07686(V-set)",6,"VAL B   2;ALA B  24;MET B  34;ASN B  72;VAL B  77;ALA B  96","None","1.15A","3qxvC-5hvfB:18.9","3qxvC-5hvfB:69.35"],["3QXV_C_MTXC2000_1","5iml","Camelidae","NANOBODY","PF07686(V-set)",6,"ALA B  23;MET B  33;ARG B  71;ASN B  73;VAL B  78;ALA B  97","None","0.72A","3qxvC-5imlB:24.1","3qxvC-5imlB:75.40"],["3QXV_C_MTXC2000_1","5j1s","Vicugna pacos","VHH DOMAIN BS-2","PF07686(V-set)",6,"ALA C  25;MET C  35;ARG C  72;ASN C  74;VAL C  79;ALA C  98","None","0.90A","3qxvC-5j1sC:19.7","3qxvC-5j1sC:66.17"],["3QXV_C_MTXC2000_1","5j1s","Vicugna pacos","VHH DOMAIN BS-2","PF07686(V-set)",5,"VAL C   3;ALA C  25;MET C  35;VAL C  79;ALA C  98","None","0.72A","3qxvC-5j1sC:19.7","3qxvC-5j1sC:66.17"],["3QXV_C_MTXC2000_1","5j57","Vicugna pacos","VHH SINGLE CHAIN ANTIBODY V5E1","PF07686(V-set)",5,"ALA B  24;ARG B  72;ASN B  74;VAL B  79;ALA B  98","None","0.44A","3qxvC-5j57B:20.9","3qxvC-5j57B:65.60"],["3QXV_C_MTXC2000_1","5ja8","Lama glama","NANOBODY 2","PF07686(V-set)",6,"VAL B   3;ALA B  25;ARG B  73;ASN B  75;VAL B  80;ALA B  99","None","0.66A","3qxvC-5ja8B:20.4","3qxvC-5ja8B:70.16"],["3QXV_C_MTXC2000_1","5ja9","Lama glama","NANOBODY 6","PF07686(V-set)",6,"VAL A   3;ALA A  25;MET A  35;ARG A  73;ASN A  75;ALA A  99","None","0.89A","3qxvC-5ja9A:20.4","3qxvC-5ja9A:68.55"],["3QXV_C_MTXC2000_1","5jmo","Camelus dromedarius","CAMELID VHH FRAGMENT","PF07686(V-set)",5,"VAL C   2;ALA C  24;MET C  34;ARG C  72;ASN C  74","None","0.80A","3qxvC-5jmoC:20.2","3qxvC-5jmoC:63.71"],["3QXV_C_MTXC2000_1","5jqh","Lama glama","NANOBODY60, NB60","no annotation",5,"MET D  34;ARG D  71;ASN D  73;VAL D  78;ALA D  97","None","0.75A","3qxvC-5jqhD:19.5","3qxvC-5jqhD:70.16"],["3QXV_C_MTXC2000_1","5lhq","Vicugna pacos","CAMELID-DERIVED ANTIBODY FRAGMENT NB7","PF07686(V-set)",6,"VAL B   2;ALA B  24;ARG B  72;ASN B  74;VAL B  79;ALA B  98","None","0.57A","3qxvC-5lhqB:21.9","3qxvC-5lhqB:64.66"],["3QXV_C_MTXC2000_1","5lhr","Vicugna pacos","CAMELID-DERIVED ANTIBODY FRAGMENT NB22","PF07686(V-set)",6,"ALA B  24;MET B  34;ARG B  72;ASN B  74;VAL B  79;ALA B  98","None","0.89A","3qxvC-5lhrB:20.2","3qxvC-5lhrB:76.00"],["3QXV_C_MTXC2000_1","5lmj","Lama glama","NANOBODY","PF07686(V-set)",6,"ALA A  24;MET A  34;ARG A  71;ASN A  73;VAL A  78;ALA A  94","None","0.93A","3qxvC-5lmjA:20.4","3qxvC-5lmjA:73.23"],["3QXV_C_MTXC2000_1","5lmj","Lama glama","NANOBODY","PF07686(V-set)",6,"VAL A   2;ALA A  24;ARG A  71;ASN A  73;VAL A  78;ALA A  94","None","0.84A","3qxvC-5lmjA:20.4","3qxvC-5lmjA:73.23"],["3QXV_C_MTXC2000_1","5lwf","Lama glama","CAMELID HEAVY-CHAIN ANTIBODY VARIABLE FRAGMENT CAB-G10S","no annotation",7,"VAL C   5;ALA C  27;MET C  37;ARG C  75;ASN C  77;VAL C  82;ALA C 101","None","0.70A","3qxvC-5lwfC:21.5","3qxvC-5lwfC:68.80"],["3QXV_C_MTXC2000_1","5mwn","Lama glama","LLAMA NANOBODY RAISED AGAINST TSSK, NBK27","PF07686(V-set)",5,"VAL N   2;ALA N  24;MET N  34;VAL N  78;ALA N  97","None","0.78A","3qxvC-5mwnN:18.2","3qxvC-5mwnN:67.46"],["3QXV_C_MTXC2000_1","5o02","Vicugna pacos","NANOBODY (VHH) NANO-4","PF07686(V-set)",5,"VAL C   2;MET C  34;ARG C  72;ASN C  74;ALA C  98","None","0.47A","3qxvC-5o02C:21.6","3qxvC-5o02C:68.55"],["3QXV_C_MTXC2000_1","5o04","Vicugna pacos","NANOBODY (VHH) NANO-26","PF07686(V-set)",5,"VAL E   2;ALA E  24;ARG E  71;ASN E  73;VAL E  78","None","0.66A","3qxvC-5o04E:18.8","3qxvC-5o04E:65.32"],["3QXV_C_MTXC2000_1","5o8f","Lama glama","NANOBODY NB25","no annotation",5,"MET L  34;ARG L  72;ASN L  74;VAL L  79;ALA L  98","None","0.44A","3qxvC-5o8fL:21.7","3qxvC-5o8fL:68.46"],["3QXV_C_MTXC2000_1","5omn","Vicugna pacos","NANOBODY (VHH) NANO-27","PF07686(V-set)",5,"VAL C   2;ALA C  24;MET C  34;ARG C  71;ASN C  73","None","0.77A","3qxvC-5omnC:19.7","3qxvC-5omnC:65.32"],["3QXV_C_MTXC2000_1","5ovw","Lama glama","NANOBODY","no annotation",5,"ALA G  46;ARG G  94;ASN G  96;VAL G 101;ALA G 120","None","0.44A","3qxvC-5ovwG:21.7","3qxvC-5ovwG:59.57"],["3QXV_C_MTXC2000_1","5tr8","Mus musculus","441D6 FAB HEAVY CHAIN","no annotation",5,"VAL H   2;ALA H  24;MET H  34;ARG H  71;ASN H  73","None","0.80A","3qxvC-5tr8H:19.1","3qxvC-5tr8H:54.88"],["3QXV_C_MTXC2000_1","5u68","Homo sapiens","MPE8","PF07686(V-set)",5,"VAL E  21;ALA E  43;MET E  53;ARG E  91;ASN E  93","None","0.80A","3qxvC-5u68E:21.0","3qxvC-5u68E:61.72"],["3QXV_C_MTXC2000_1","5uk4","Vicugna pacos","ANTI-VESICULAR STOMATITIS VIRUS N VHH","no annotation",6,"VAL p   2;MET p  34;ARG p  72;ASN p  74;VAL p  79;ALA p  98","None","0.69A","3qxvC-5uk4p:21.6","3qxvC-5uk4p:71.43"],["3QXV_C_MTXC2000_1","5vaq","Lama glama","NB914","no annotation",6,"ALA B  24;SER B  30;ARG B  72;ASN B  74;VAL B  79;ALA B  98","None","0.98A","3qxvC-5vaqB:23.3","3qxvC-5vaqB:75.00"],["3QXV_C_MTXC2000_1","5vf6","Gallus gallus","SINGLE CHAIN VARIABLE FRAGMENT","no annotation",6,"VAL A 125;ALA A 147;MET A 157;ARG A 195;ASN A 197;VAL A 202","None","0.97A","3qxvC-5vf6A:20.4","3qxvC-5vf6A:21.09"],["3QXV_C_MTXC2000_1","5vk2","Homo sapiens","FAB 37.7H HEAVY CHAIN","PF07654(C1-set);PF07686(V-set)",5,"VAL D   3;ALA D  25;MET D  35;ARG D  74;ASN D  76","None","0.79A","3qxvC-5vk2D:20.5","3qxvC-5vk2D:40.70"],["3QXV_C_MTXC2000_1","5vxj","Vicugna pacos","SINGLE-DOMAIN ANTIBODY JMK-E3","no annotation",6,"VAL B   2;MET B  34;ARG B  72;ASN B  74;VAL B  79;ALA B  98","None","0.71A","3qxvC-5vxjB:19.5","3qxvC-5vxjB:63.08"],["3QXV_C_MTXC2000_1","5vxl","Vicugna pacos","SINGLE-DOMAIN ANTIBODY JPS-G3","no annotation",6,"ALA B  24;MET B  34;ARG B  73;ASN B  75;VAL B  80;ALA B  99","None","0.74A","3qxvC-5vxlB:20.3","3qxvC-5vxlB:66.41"],["3QXV_C_MTXC2000_1","5vxm","Vicugna pacos","SINGLE-DOMAIN ANTIBODY 20IPAD","no annotation",5,"VAL B   2;ARG B  72;ASN B  74;VAL B  79;ALA B  98","None","0.70A","3qxvC-5vxmB:23.0","3qxvC-5vxmB:70.31"],["3QXV_C_MTXC2000_1","5wb1","Human betaherpesvirus 5;Lama glama","ENVELOPE PROTEIN US28, NANOBODY 7 FUSION PROTEIN","no annotation",6,"VAL A1002;ALA A1024;MET A1034;ASN A1073;VAL A1078;ALA A1097","None","0.94A","3qxvC-5wb1A:18.3","3qxvC-5wb1A:15.08"],["3QXV_C_MTXC2000_1","5xaj","Homo sapiens","FABHM14C10 HEAVY CHAIN","PF07654(C1-set);PF07686(V-set)",5,"VAL A   2;ALA A  24;MET A  34;ASN A  74;VAL A  79","None","0.78A","3qxvC-5xajA:21.2","3qxvC-5xajA:64.29"],["3QXV_C_MTXC2000_1","5y9f","Mus musculus","HEAVY CHAIN OF FAB FRAGMENT OF ANTIBODY 28F10","no annotation",5,"VAL L   2;ALA L  24;MET L  34;ARG L  72;ASN L  74","None","0.74A","3qxvC-5y9fL:20.3","3qxvC-5y9fL:57.94"],["3QXV_C_MTXC2000_1","5yy5","-","-","no annotation",5,"VAL C   2;ALA C  24;MET C  34;ARG C  71;ASN C  73","None","0.69A","3qxvC-5yy5C:19.6","3qxvC-5yy5C:undetectable"],["3QXV_C_MTXC2000_1","6d11","Homo sapiens","1450 ANTIBODY, HEAVY CHAIN","no annotation",5,"VAL A   2;MET A  34;ARG A  71;ASN A  73;VAL A  78","None","0.55A","3qxvC-6d11A:20.1","3qxvC-6d11A:44.72"],["3QXV_C_MTXC2000_1","6ehg","Lama glama","HC3NB1","no annotation",6,"ALA C  24;MET C  34;ARG C  72;ASN C  74;VAL C  79;ALA C  98","None","0.70A","3qxvC-6ehgC:22.4","3qxvC-6ehgC:57.14"],["3QXV_C_MTXC2000_1","6fe4","Vicugna pacos","NB113","no annotation",5,"VAL F   2;ALA F  24;MET F  34;ARG F  72;ASN F  74","None","0.81A","3qxvC-6fe4F:20.8","3qxvC-6fe4F:66.25"],["3QXV_C_MTXC2000_1","6gzp","Lama glama","NANOBODY","no annotation",6,"VAL A   2;ALA A  24;MET A  34;ARG A  71;ASN A  73;ALA A  94","None","0.71A","3qxvC-6gzpA:22.0","3qxvC-6gzpA:undetectable"],["3QXV_C_MTXC2000_1","8fab","Homo sapiens","IGG1-LAMBDA HIL FAB (HEAVY CHAIN)","PF07654(C1-set);PF07686(V-set)",5,"VAL B   2;ALA B  24;MET B  34;ARG B  72;ASN B  74","None","0.79A","3qxvC-8fabB:22.0","3qxvC-8fabB:59.52"]]